Applying Evidence-Based Guidelines to Reduce Hospitalizations and Readmissions for Chronic Heart Failure

 
Release Date: January 31, 2019
Last Reviewed: January 31, 2019
Expiration Date: January 31, 2020
Time to Complete Activity:  1.0 hour
*This activity expired for credit on January 31, 2020 and is no longer available for credit



This activity is provided by Paradigm Medical Communications, LLC.   
Faculty
Akshay Suvas Desai, MD, MPH (Chair)
Associate Professor of Medicine
Harvard Medical School
Director, Cardiomyopathy and Heart Failure
Advanced Heart Disease Section
Cardiovascular Division
Brigham and Women’s Hospital
Boston, MA
 
Steering Committee
Akshay Suvas Desai, MD, MPH (Chair)
Associate Professor of Medicine
Harvard Medical School
Director, Cardiomyopathy and Heart Failure
Advanced Heart Disease Section
Cardiovascular Division
Brigham and Women’s Hospital
Boston, MA
 
Kirkwood F. Adams Jr, MD
Associate Professor of Medicine and Radiology
Department of Medicine
Division of Cardiology
UNC School of Medicine
University of North Carolina
Chapel Hill, NC
 
Alpesh Amin, MD, MBA
Professor and Chair, Department of Medicine
Executive Director, Hospitalist Program
University of California, Irvine
Irvine, CA
 
Target Audience
This activity has been designed to meet the educational needs of cardiologists, hospitalists, and pharmacists. It may also be of benefit to primary care physicians and other healthcare providers who treat chronic heart failure (CHF).

Statement of Need
Attaining improved readmission and mortality outcomes for patients with CHF continues to challenge hospital clinicians. Despite the establishment of evidence-based treatment guidelines, use of recommended, life-saving, hospitalization-reducing CHF medications has been historically suboptimal. Novel therapies that have recently entered the arena are included in current guidelines, but many clinicians are not up to date with the latest guidelines or best practices for incorporating these novel therapies into regimens for patients with CHF.       
 
Learning Objectives
Upon proper completion of this activity, participants should be better able to:
  • Identify how the pathophysiology of CHF relates to mechanisms of action for newer therapies.
  • Practice appropriate, evidence-based use of newer CHF therapies for patients with CHF.
  • Outline treatment strategies to reduce hospitalizations and readmissions for patients with CHF in accordance with current guideline recommendations.
     
Table of Contents
  • Disease burden and epidemiology of heart failure
  • Core concepts in heart failure pathophysiology and targets for pharmacologic intervention (emphasizing HFrEF)
  • Evidence-based data supporting sacubitril/valsartan and ivabradine
  • Updated AHA/ACC/HFSA guidelines in clinical practice
  • Recent Data on Acute Decompensated Heart Failure in Hospitalized Patients
 
Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Pharmacist Accreditation and Designation Statement
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.0 hour (0.10 CEU) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. (Universal Activity Number – 0761-9999-18-313-H01-P; 0761-9999-18-313-H01-T)

This is a knowledge-based activity.

This activity is jointly provided by Educational Review Systems, Inc and Paradigm Medical Communications, LLC. 
                                                                                     
 
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
 
PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
 
Disclosure of Commercial Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
 
Instructions for Participation
To receive credit, you should:
  • Follow instructions to register or log in with your professional information and complete the preactivity assessment
  • View the online activity in its entirety.
  • Complete and submit the online posttest and evaluation.
A certificate of participation/statement of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

Please note: To claim CPE credit, please make sure you include your date of birth and NABP number. All credit information will be uploaded into CPE Monitor within 30 days.

For questions regarding CME/CPE credit, contact the Paradigm CME Department at (845) 398-5949.
 
There is no fee required for participation in this activity.

Hardware/Software Requirements
This certified CME/CPE activity is designed using HTML5 video and audio. As you navigate the video using the supplied controls, the slides will sync to the speaker.
 
Supported Browsers:
For Desktops (Windows/Mac)
Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher
 
For Tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher
 
Technical Support: If you have any technical problems or playback issues email us at contactus@paradigmmc.com.
 
Disclosures
In accordance with ACCME and ACPE requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.

Akshay Suvas Desai, MD, MPH
Grant/Research Support: Novartis Pharmaceuticals Corporation
Retained Consultant: Abbott Laboratories; AstraZeneca; DalCor Pharmaceuticals; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc; Relypsa, Inc; Signature Medical, Inc
 
Kirkwood F. Adams Jr, MD
Grant/Research Support: Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc; Merck & Co, Inc; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc; Roche
Retained Consultant: Cytokinetics, Inc; Relypsa, Inc
 
Alpesh Amin, MD, MBA
No financial relationships to disclose.
 
Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.
 
Educational Review Systems, Inc staff members have no financial relationships to disclose.

Independent peer reviewer has no financial relationships to disclose.

Resolution of Conflict of Interest
Paradigm Medical Communications, LLC and Educational Review Systems, Inc have implemented a system to resolve conflicts of interest for each CME/CPE activity to help ensure content objectivity, independence, fair balance, and that the content is aligned with the interest of the public. Conflicts, if any, are resolved through one or more processes. All CME/CPE content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance, ACPE Guidelines, and ACCME’s Standards for Commercial Support of Continuing Medical Education.
 
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.
 
Disclaimer
This CME/CPE activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC or Educational Review Systems, Inc. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
 
If included, signed statements of informed consent granting permission for use have been obtained for all photographs and videos in which an individual can be identified.
 
As accredited providers, Paradigm Medical Communications, LLC and Educational Review Systems, Inc activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC or Educational Review Systems, Inc.
 
Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the faculty, and do not necessarily represent those of Paradigm Medical Communications, LLC or Educational Review Systems, Inc. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC or Educational Review Systems, Inc. Paradigm Medical Communications, LLC and Educational Review Systems, Inc accept no liability for the content referenced in this activity.
 
Privacy policy
Paradigm Medical Communications, LLC and Educational Review Systems, Inc are committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
 
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
 
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC and Educational Review Systems, Inc to continuously improve the learning experience.
 
Paradigm Medical Communications, LLC and Educational Review Systems, Inc do not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC and Educational Review Systems, Inc will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC and Educational Review Systems, Inc staff members review individual test results to the extent necessary to record and track participants’ credits.
 
Contact Us
If you have any questions or comments, please email us at contactus@paradigmmc.com.
 
© 2019 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.